Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.

Aman M, Rettiganti M, Nagaraja HN, Hollway JA, McCracken J, McDougle CJ, Tierney E, Scahill L, Arnold LE, Hellings J, Posey DJ, Swiezy NB, Ghuman J, Grados M, Shah B, Vitiello B.

J Child Adolesc Psychopharmacol. 2015 Aug;25(6):482-93. doi: 10.1089/cap.2015.0005.

2.

Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.

Chen Q, Sjölander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H.

BMJ. 2014 Jun 18;348:g3769. doi: 10.1136/bmj.g3769.

3.

Psychotropic medication monitoring checklists: use and utility for children in residential care.

Ninan A, Stewart SL, Theall L, King G, Evans R, Baiden P, Brown A.

J Can Acad Child Adolesc Psychiatry. 2014 Feb;23(1):38-47.

4.

Evidence review and clinical guidance for the use of ziprasidone in Canada.

Gardner DM, Murphy AL, Kutcher S, Beaulieu S, Carandang C, Labelle A, Lalonde P, Malla A, Milliken H, O'Donovan C, Schaffer A, Soni J, Taylor VH, Williams R.

Ann Gen Psychiatry. 2013 Jan 24;12(1):1. doi: 10.1186/1744-859X-12-1.

5.

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.

Golder S, Loke YK, Bland M.

PLoS Med. 2011 May;8(5):e1001026. doi: 10.1371/journal.pmed.1001026. Epub 2011 May 3. Review.

6.

Pediatric psychotropic polypharmacy.

Zonfrillo MR, Penn JV, Leonard HL.

Psychiatry (Edgmont). 2005 Aug;2(8):14-9.

7.

Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Gruber R, Joober R, Grizenko N, Leventhal BL, Cook EH Jr, Stein MA.

J Child Adolesc Psychopharmacol. 2009 Jun;19(3):233-9. doi: 10.1089/cap.2008.0133.

8.

The child and adolescent psychiatry trials network (CAPTN): infrastructure development and lessons learned.

Shapiro M, Silva SG, Compton S, Chrisman A, DeVeaugh-Geiss J, Breland-Noble A, Kondo D, Kirchner J, March JS.

Child Adolesc Psychiatry Ment Health. 2009 Mar 25;3(1):12. doi: 10.1186/1753-2000-3-12.

9.

Suicidal ideation reports from pediatric trials for paroxetine and venlafaxine.

Carrey N, Pharm AV.

Can Child Adolesc Psychiatr Rev. 2003 Nov;12(4):101-2. No abstract available.

10.

Practitioner review: adolescent alcohol use disorders: assessment and treatment issues.

Perepletchikova F, Krystal JH, Kaufman J.

J Child Psychol Psychiatry. 2008 Nov;49(11):1131-54. doi: 10.1111/j.1469-7610.2008.01934.x. Review.

11.

Treatment for Adolescents with Depression Study (TADS): safety results.

Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNulty S, Weller E, Waslick B, Casat C, Walkup J, Pathak S, Rohde P, Posner K, March J; Columbia Suicidality Classification Group; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1440-55.

Items per page

Supplemental Content

Write to the Help Desk